Ionis Pharmaceuticals announced that its antisense oligonucleotide drug Tryngolza met primary and secondary endpoints in two Phase 3 trials (Core and Core2) targeting severe hypertriglyceridemia. The treatment significantly reduced triglyceride levels and pancreatitis episodes, paving the way for a regulatory submission to expand the indication beyond familial chylomicronemia syndrome. Ionis' first wholly owned marketed product, Tryngolza, addresses a growing multi-billion dollar market driven by obesity and diabetes prevalence. Investors responded favorably, reflecting optimism about its commercial potential.